XOMA Royalty (NASDAQ:XOMA) Posts Quarterly Earnings Results, Misses Estimates By $0.33 EPS

XOMA Royalty (NASDAQ:XOMA) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33), Zacks reports. The firm had revenue of $9.35 million for the quarter, compared to the consensus estimate of $11.47 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%.

XOMA Royalty Price Performance

Shares of XOMA traded down $1.38 during trading hours on Thursday, reaching $32.24. The stock had a trading volume of 48,685 shares, compared to its average volume of 45,996. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.88 and a current ratio of 4.88. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92. The stock has a market capitalization of $389.72 million, a PE ratio of -20.80 and a beta of 1.12. The company’s 50-day moving average is $35.92 and its two-hundred day moving average is $30.07.

Insider Transactions at XOMA Royalty

In other XOMA Royalty news, CFO Thomas M. Burns sold 4,330 shares of the stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $35.99, for a total value of $155,836.70. Following the completion of the transaction, the chief financial officer directly owned 30,079 shares in the company, valued at approximately $1,082,543.21. This trade represents a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.10% of the stock is currently owned by insiders.

Institutional Trading of XOMA Royalty

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of XOMA Royalty by 9.1% in the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after buying an additional 16,929 shares during the last quarter. Opaleye Management Inc. increased its position in XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock valued at $6,428,000 after purchasing an additional 2,044 shares during the period. Raymond James Financial Inc. bought a new position in XOMA Royalty during the 2nd quarter worth approximately $116,000. Vanguard Group Inc. lifted its position in shares of XOMA Royalty by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after purchasing an additional 29,298 shares during the period. Finally, Woodline Partners LP lifted its position in shares of XOMA Royalty by 7.9% in the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock worth $3,359,000 after purchasing an additional 12,284 shares during the period. Institutional investors own 95.92% of the company’s stock.

Analyst Upgrades and Downgrades

XOMA has been the subject of several research analyst reports. Wall Street Zen upgraded shares of XOMA Royalty from a “hold” rating to a “buy” rating in a research report on Monday, August 11th. Zacks Research lowered XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of XOMA Royalty in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, XOMA Royalty currently has an average rating of “Hold” and a consensus target price of $69.50.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.